Short answer
ABEONA THERAPEUTICS INC. (ABEO) filed its Q3 2025 10-Q quarterly report on Nov 12, 2025 for the quarter ended Sep 30, 2025. Quarterly revenue was $0 with net income of −$5M.
Q3 2025 key financials · XBRL
- Revenue
- $0
- Net income
- −$5M
- +82.9% YoY · −104.7% QoQ
- EPS (diluted)
- −$0.12
- +82.6% YoY · −107.0% QoQ
Source: XBRL data from the ABEONA THERAPEUTICS INC. (ABEO) Q3 2025 10-Q on SEC EDGAR. USD.
ABEONA THERAPEUTICS INC. Q3 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Quarterly revenue not disclosed; nine-month license revenue $0.4M vs $0
- Operating margin not provided; operating loss $24.0M vs $15.3M YoY
- ZEVASKYN production: $0.5M cost of sales from unreleased August batch
- Cash resources $207.5M; operating cash use $58.4M through September 30
- Outlook: funding sufficient through at least 12 months; additional financing may be needed
Risk Factors
- New tariff risk triggered by U.S. trade-policy changes, potentially increasing research costs and disrupting pharmaceutical supply chains
- Commercial-stage transition after FDA approval on April 28, 2025, with no ZEVASKYN® revenue recorded to date
- Section 382 ownership changes may materially limit use of $416.1 million federal NOL carryforwards
- FDA workforce reductions, funding pressures, or shutdowns could delay regulatory reviews and approvals
- ZEVASKYN® commercialization depends on patient demand, reimbursement, pricing, and market acceptance
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other ABEONA THERAPEUTICS INC. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.